Breast Cancer News From Medical News Today
3 Feb 2012 at 3:00am
Using some of the most powerful nuclear magnetic resonance equipment available, researchers at the University of California, Davis, are making discoveries about the shape and structure of biological molecules - potentially leading to new ways to treat or prevent diseases such as breast cancer and Alzheimer's disease...
3 Feb 2012 at 3:00am
Genome Research publishes online and in print a special issue entitled, "Cancer Genomics," highlighting insights gained form cutting-edge genomic and epigenomic analyses of cancer...
3 Feb 2012 at 2:00am
Contrary to earlier findings, surgical breast biopsies may not be as overused as previously thought, according to a study in the February issue of the Journal of the American College of Radiology. Surgical breast biopsies are more invasive than needle biopsies, requiring an incision and the use of general anesthesia...
2 Feb 2012 at 11:00am
Breast cancer charity, Susan G. Komen for the Cure, says that dropping Planned Parenthood from its granting process is not political, and says it is "dismayed and extremely disappointed" that its action has been mischaracterized. The charity says it has taken actions to make its granting process stronger and more effective, resulting in Planned Parenthood being dropped from its list of grantees...
2 Feb 2012 at 3:00am
A study of 64,659 women, recently published in the journal Academic Radiology, found that while 1,246 of these women were at high enough breast cancer risk to recommend additional screening with MRI, only 173 of these women returned to the clinic within a year for the additional screening...
1 Feb 2012 at 1:00pm
22.9% of breast cancer patients who undergo partial mastectomies need further operations to remove more tissue, researchers reported in JAMA (Journal of the American Medical Association)...
30 Jan 2012 at 2:00am
In 2011 - to the consternation of women everywhere - a systematic review of randomized clinical trials showed that routine mammography was of little value to younger women at average or low risk of breast cancer...
29 Jan 2012 at 2:00am
In a study that holds major implications for breast cancer research as well as basic cell biology, scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered a rotational motion that plays a critical role in the ability of breast cells to form the spherical structures in the mammary gland known as acini...
27 Jan 2012 at 12:00pm
Not only are relatively few Americans screened for cancer, but there are considerable disparities between ethnic and racial groups in the country, says a new report issued by NCI (National Cancer Institute) and the CDCF (Centers for Disease Control and Prevention). The authors added that screening rates are especially low among Hispanic and Asian Americans...
26 Jan 2012 at 6:00pm
The first national breast cancer tissue bank in the UK has opened its vaults of precious breast cancer tissue to all researchers in the UK and Ireland, providing a massive boost to breast cancer research. The bank is a unique collaboration of four leading research institutions and the NHS...
26 Jan 2012 at 6:00am
Avastin and Sutent, two cancer drugs, do not lead to longer survival in breast cancer patients, probably because they encourage an increase in the number cancer stem cells in breast tumors, according to a study carried out on mice by researchers from the Michigan Comprehensive Cancer Center, and published in the Proceedings of the National Academy of Sciences (early edition)...
24 Jan 2012 at 12:00pm
Around 75% of the 48,000 women annually diagnosed with breast cancer in the UK suffer from an estrogen receptor positive tumor, which implies the involvement of the hormone estrogen in cancer growth...
24 Jan 2012 at 5:00am
Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online in the Journal of Experimental Medicine. The single protein is HSP90, which acts as a chaperone to protect other proteins in the cell...
24 Jan 2012 at 4:00am
An international team of researchers has discovered 13 new regions of the genome associated with the timing of menopause. These genes shed light on the biological pathways involved in reproductive lifespan and will provide insights into conditions connected to menopause, such as breast cancer and heart disease...
24 Jan 2012 at 4:00am
Quality of life in younger patients treated for breast cancer is seriously compromised and these women suffer from severe psychological distress, infertility, premature menopause, a decrease in physical activity and weight gain, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center...
|
MyBreastCancerNetwork.com - Latest Breast Cancer News
18 Nov 2011 at 11:07am
n June, an FDA advisory committee recommended that Avastin's approval be revoked, citing evidence that suggests the drug has limited effectiveness in metastatic breast cancer, but that it dramatically raises the risk of life-threatening side effects.
21 Oct 2011 at 1:23pm
Research suggests that the number of medical tests done in early-stage diabetes may explain why women are more likely to be diagnosed with breast cancer too.
3 Jun 2011 at 10:34am
The U.S. has unveiled a new healthy eating icon called MyPlate, to replace the older and more controversial food pyramid.
5 Apr 2011 at 10:26am
The easiest way to reduce your exposure to hormone-disrupting chemicals such as BPA (bisphenol A) may be to eat fresh, unpackaged foods, a new report suggests.
1 Mar 2011 at 9:16am
Researchers at Queen's University Belfast have discovered a new way of causing breast cancer cells to self destruct.
1 Mar 2011 at 8:19am
A new study has found that the more times a woman gives birth, the greater her risk of developing triple-negative breast cancer.
25 Jan 2011 at 4:06pm
The experimental breast cancer drug Iniparib appears to shrink tumors, increase the time tumors take to progress, and prolongs survival in women with triple negative breast cancer.
25 Jan 2011 at 12:21pm
Women who smoke before menopause are more likely to develop breast cancer, a new study finds.
12 Jan 2011 at 7:53am
Despite what your parents told you, swallowed gum won't take 7 years to digest. And that's just one of the things they got wrong!
16 Dec 2010 at 1:17pm
U.S. Food and Drug Administration officials have recommended revoking approval of the medication Avastin (bevacizumab) for the treatment of breast cancer.
29 Nov 2010 at 5:01pm
Treating yourself to small servings of extra food during the holiday season can cause you to pack on the pounds, but sneaking small extra servings of exercise may help, experts say.
25 Oct 2010 at 5:19pm
Maintaining support from family and informal support groups remains important even after women finish chemotherapy, a new study has found.
25 Oct 2010 at 10:07am
Taking an extra 2millimeter margin of healthy breast tissue during breast surgery may help prevent residual breast cancer, a new study suggests.
25 Oct 2010 at 9:56am
Researchers found that it didn't matter which muscle was tightened--finger, calf, hand, or biceps, but the will-power boost only worked during the moment they faced the self-control dilemma.
18 Oct 2010 at 9:37am
A two-hour weekly Hatha yoga class that combines poses with meditation and discussion may help people who suffer from fibromyalgia and chronic pain, such as arthritis.
|
Breast Cancer Research - Latest Articles
by Gitte Sorensen
2 Feb 2012 at 6:00pm
IntroductionGlucocorticoids are widely prescribed drugs. In the human body, glucocorticoid is the main stress hormone, and controls a variety of physiological and cellular processes, including metabolism and immune response. It belongs to the same steroid superfamily as estrogens, which are known to play a role in breast cancer. However, the effect of glucocorticoid use on the risk of breast cancer is not clear.
Methods:
We conducted a case-control study using population-based medical databases from Northern Denmark (1.8 million inhabitants) to investigate the association between glucocorticoid prescriptions and breast cancer risk. The study included 9,488 incident breast cancer cases diagnosed between 1994 and 2008 and 94,876 population controls. We estimated the odds ratios (ORs) and 95% confidence intervals (CIs) associating glucocorticoid use with breast cancer occurrence, controlling for prescriptions of postmenopausal hormone replacement therapy, anti-diabetics, immunosuppressive drugs, and hospital diagnosis of obesity, diabetes, chronic pulmonary diseases and autoimmune diseases.
Results:
We found no effect on breast cancer risk in ever users (>2 prescriptions) of any glucocorticoids (adjusted OR (aOR)=1.0; 95% CI: 0.96, 1.1), systemic glucocorticoids (aOR=1.0; 95% CI: 0.96, 1.1), or inhaled glucocorticoids (aOR=1.0; 95% CI: 0.95, 1.1), each compared to never users of any glucocorticoids. Associations for recent use (preceding 2 years) and former use (more than 2 years earlier) were near null in all dose categories (low, medium and high number of prescriptions). Intensity of systemic glucocorticoid use (cumulative prednisolone equivalent doses), regardless of duration (<1, 1-5, 5+ years), was also not associated with breast cancer risk.
Conclusions:
Overall, our study provides no evidence that glucocorticoid use affects the risk of breast cancer.
by Jose Perez
30 Jan 2012 at 6:00pm
The current understanding of the molecular biology of breast cancer presents an extremely complex portrait of the disease. Based on this knowledge, considerable efforts are being made to identify biomarkers that will predict the response to a specific treatment while minimizing the risk of unnecessary side effects. In breast cancer, the Ki67 index has been associated with poor prognosis and might play a relevant role in predicting benefit from adjuvant docetaxel, as observed in the article accompanying this editorial. Taxanes are one of the most active cytotoxic agents for breast cancer. However, the role of taxane-based chemotherapy as adjuvant treatment of early breast cancer remains controversial in some subsets of patients. For this reason, the Ki67 index might help to better define the group of patients who could have the optimal benefit.
by Yu Sun
30 Jan 2012 at 6:00pm
IntroductionWe have recently synthesized phospho-ibuprofen (MDC-917; P-I), a safer derivative of ibuprofen, which has shown anticancer activity. We investigated its efficacy and mechanism of action in the treatment of breast cancer in preclinical models.
Methods:
We evaluated the anti-breast cancer efficacy of P-I alone or incorporated into liposomes (Lipo-P-I) in human ER (+) (MCF-7) and triple-negative (ER(-), PgR(-) and HER2(-); MDA-MB231) breast cancer cell lines, as they represent the most frequent (ER(+)) and the most difficult to treat (triple-negative) subtypes of breast cancer , and their xenografts in nude mice. We assessed the effect of P-I on a) the levels of reactive oxygen nitrogen species in response to P-I using molecular probes; b) the thioredoxin system (expression and redox status of thioredoxin-1 (Trx-1) and thioredoxin reductase activity); c) cyclooxygenase 2 (COX-2), nuclear factor KB (NF-KB) and mitogen-activated protein kinase (MAPK) cell signaling; and d) the growth of xenografts with stably knocked-down Trx-1.
Results:
Compared to controls, a) P-I 400 mg/kg/day inhibited the growth of MDA-MB231 xenografts 266%; and b) P-I 300 mg/kg/day inhibited the growth of MCF-7 xenografts 51% and Lipo-P-I at the same dose 181%. In both cell lines, P-I induced oxidative stress and suppressed the Trx system (oxidized Trx-1 and decreased its expression; inhibited thioredoxin reductase activity). These changes triggered downstream redox signaling: the activity of NF-KB was suppressed and the Trx-1-ASK1 complex was dissociated, activating the p38 and JNK MAPK cascades. Trx-1 knockdown abrogated P-I's anticancer effect in vitro and in vivo.
Conclusions:
P-I is safe and effective against breast cancer. Liposomal formulation enhances its efficacy; its effect is heavily dependent on the induction of oxidative stress and the suppression of the thioredoxin system. P-I merits further evaluation as an agent for the treatment of breast cancer.
by Wen Yee Chay
29 Jan 2012 at 6:00pm
IntroductionThe Gail model (GM) is a risk-assessment model used in individual estimation of the absolute risk of invasive breast cancer, and has been applied to both clinical counselling and breast cancer prevention studies. Although the GM has been validated in several Western studies, its applicability outside North America and Europe remains uncertain. The Singapore Breast Cancer Screening Project (SBCSP) is a nation-wide prospective trial of screening mammography conducted between Oct 1994 and Feb 1997, and is the only such trial conducted outside North America and Europe to date. With the long-term outcomes from this study, we sought to evaluate the performance of GM in prediction of individual breast cancer risk in an Asian-developed country.
Methods:
The study population comprised of 28,104 women aged 50 to 64 years who participated in the SBSCP and did not have breast cancer detected during screening. The national cancer registry was used to identify incident cases of breast cancer. To evaluate the performance of the GM, we compared the expected number of invasive breast cancer cases predicted by the model to the actual number of cases observed within 5-year and 10-year follow-up. Pearson's Chi-square test was used to test the goodness of fit between the expected and observed cases of invasive breast cancers.
Results:
The ratio of expected to observed number of invasive breast cancer cases within 5-year from screening was 2.51 (95% confidence interval 2.14 - 2.96). The GM over-estimated breast cancer risk across all age groups, with the discrepancy highest among older women aged 60 - 64 years (E/O = 3.53, 95% CI = 2.57 - 4.85). The model also over-estimated risk for the upper 80% of women with highest predicted risk. The overall E/O ratio for the 10-year predicted breast cancer risk was 1.85 (1.68 - 2.04).
Conclusions:
The GM over-predicts the risk of invasive breast cancer in an Asian developed-country setting as demonstrated in a large prospective trial, with the largest difference seen in older women aged between 60 and 64 years old. The reason for the discrepancy is likely to be multifactorial, including a true reduction of breast cancer, as well as lower mammographic screening prevalence locally.
by Oriana Hawkins
25 Jan 2012 at 6:00pm
The contribution of CXCR7 to the tumor microenvironment has introduced a new level of complexity to CXCL12 signaling in breast cancer. In the previous issue of Breast Cancer Research, Hernandez and colleagues delineate the roles of CXCR4 and CXCR7 in tumor invasion and metastasis. The authors demonstrate that co-expression of CXCR7 and CXCR4 results in inhibition of CXCL12-mediated invasion, reduced intravasation of tumor cells into the vasculature, and fewer lung metastases compared with parental tumors. The results of this study suggest the combination of small molecule inhibitors of CXCR4 and CXCR7 could dramatically reduce invasion, intravasation, and metastasis and could be highly beneficial for the treatment of invasive breast cancer.
by Karla Kerlikowske
24 Jan 2012 at 6:00pm
Few studies have investigated the association of non-dense area or fatty breasts in conjunction with breast density and breast cancer risk. Two articles in a recent issue of Breast Cancer Research investigate the role of absolute non-dense breast area measured on mammograms and find conflicting results: one article finds that non-dense breast area has a modest positive association with breast cancer risk, whereas the other finds that non-dense breast area has a strong protective effect to reduce breast cancer risk. Understanding the interplay of body mass index, menopause status, and measurement of non-dense breast area would help to clarify the contribution of non-dense breast area to breast cancer risk.
by Desheng Weng
24 Jan 2012 at 6:00pm
IntroductionIt is still uncertain whether metastasis is predominantly an early or late event in tumor progression. The detection of early metastases and cells responsible for the dissemination may therefore have significant clinical implications.
Methods:
Lung dissemination and/or metastasis were investigated in mice carrying the polyomavirus middle-T oncogene (PyMT) during different stages of mammary tumorigenesis using the colony forming assay. Immunocytochemical or immunohistochemical staining was used to identify subpopulations of cells responsible for lung dissemination and metastasis. Histological examination was used to show primary and metastatic tumors. The tumor-initiating and metastatic capacity of cells expressing stem cell markers was assessed in syngeneic wild-type (WT) mice whose mammary fat pads were injected with these cells.
Results:
Metastatic mammary epithelial cells were detected in the lungs of mice carrying the PyMT oncogene (MMT mice). These cells were observed early in breast tumorigenesis when the mammary tree appeared by histological inspection to be normal (or at a premalignant stage), suggesting the possession of disseminating and metastatic capacity even before full malignant transformation. Some of the disseminated cells and lung metastases displayed surface stem cell markers. These findings suggest that stem cells from apparently precancerous primary lesions could be a source of metastasis. Indeed, injection of lung tissue cells from MMT mice into syngeneic WT mice resulted in the formation of mammary tumors. These tumors resembled their parent mammary tumors in the MMT donors as well as grafted tumors derived from mammary tumor cells. Furthermore, when we injected lung tissue cells from GFP MMT mice into the fat pads of recipient WT mice, disseminated or metastatic GFP-expressing cells were detected in the lungs, lymph nodes and blood of the recipient WT mice. We finally identified a subpopulation of mammary epithelial/tumor cells expressing CD44 and Sca1 that was largely responsible for dissemination and metastasis in MMT mice.
Conclusions:
The tumorigenic and metastatic potential of a subpopulation of mammary epithelial/tumor cells in MMT mice is endowed relatively early in mammary neoplasms and suggests a potential role for cancer stem cell sub-populations in metastasis.
by Juncheng Dai
22 Jan 2012 at 6:00pm
IntroductionRecently, several genome-wide association studies (GWAS) have identified novel single nucleotide polymorphisms (SNPs) associated with breast cancer risk. However, most of the studies were conducted among Caucasians and only one from Chinese.
Methods:
In the current study, we first tested whether 15 SNPs identified by previous GWAS were also breast cancer marker SNPs in this Chinese population. Then, we grouped the marker SNPs, and modeled them with clinical risk factors, to see the usage of these factors in breast cancer risk assessment. Two methods (risk factors counting and OR weighted risk scoring) were used to evaluate the cumulative effects of the 5 significant SNPs and two clinical risk factors (age at menarche and age at first live birth).
Results:
Five SNPs located at 2q35, 3p24, 6q22, 6q25 and 10q26 were consistently associated with breast cancer risk in both testing set (878 cases and 900 controls) and validation set (914 cases and 967 controls) samples. Overall, all of the five SNPs contributed to breast cancer susceptibility in dominant genetic model (2q35, rs13387042: adjusted OR=1.26, P=0.006; 3q24.1, rs2307032: adjusted OR=1.24, P=0.005; 6q22.33, rs2180341: adjusted OR=1.22, P=0.006; 6q25.1, rs2046210: adjusted OR=1.51, P=2.40x10-8; 10q26.13, rs2981582: adjusted OR=1.31, P=1.96x10-4). Risk score analyses (AUC: 0.649, 95%CI: 0.631-0.667; sensitivity=62.60%, specificity=57.05%) presented better discrimination than that by risk factors counting (AUC: 0.637, 95%CI: 0.619-0.655; sensitivity=62.16%, specificity=60.03%) (P<0.0001). Absolute risk was then calculated by the modified Gail model and an AUC of 0.658 (95% CI=0.640-0.676) (sensitivity=61.98%, specificity=60.26%) was obtained for the combination of 5 marker SNPs, age at menarche and age at first live birth.
Conclusions:
This study shows that 5 GWAS identified variants were also consistently validated in this Chinese population and combining these genetic variants with other risk factors can improve the risk predictive ability of breast cancer. However, more breast cancer associated risk variants should be incorporated to optimize the risk assessment.
by Szeman Chan
19 Jan 2012 at 6:00pm
IntroductionAlthough breast cancers expressing estrogen receptor-alpha (ERalpha) and progesterone receptors (PR) are the most common form of mammary malignancy in humans, it has been difficult to develop a suitable mouse model showing similar steroid hormone responsiveness. STAT transcription factors play critical roles in mammary gland tumorigenesis, but the precise role of STAT1 remains unclear. Herein, we show that a subset of human breast cancers display reduced STAT1 expression and that mice lacking STAT1 surprisingly develop ERalpha+/PR+ mammary tumors.
Methods:
We used a combination of approaches, including histological examination, gene targeted mice, gene expression analysis, tumor transplantaion, and immunophenotyping, to pursue this study.
Results:
45% (37/83) of human ERalpha+ and 22% (17/78) of ERalpha- breast cancers display undetectable or low levels of STAT1 expression in neoplastic cells. In contrast, STAT1 expression is elevated in epithelial cells of normal breast tissues adjacent to the malignant lesions, suggesting that STAT1 is selectively downregulated in the tumor cells during tumor progression. Interestingly, the expression levels of STAT1 in the tumor-infiltrating stromal cells remain elevated, indicating that single-cell resolution analysis of STAT1 level in primary breast cancer biopsies is necessary for accurate assessment. Female mice lacking functional STAT1 spontaneously develop mammary adenocarcinomas that comprise >90% ERalpha+/PR+ tumor cells, and depend on estrogen for tumor engraftment and progression. Phenotypic markers analyses demonstrate that STAT1-/- mammary tumors arise from luminal epithelial cells, but not myoepithelial cells. In addition, the molecular signature of the STAT1-/- mammary tumors overlaps closely to that of human luminal breast cancers. Finally, introduction of wildtype STAT1, but not a STAT1 mutant lacking the critical Tyr701 residue, into STAT1-/- mammary tumor cells results in apoptosis, demonstrating that the tumor suppressor function of STAT1 is cell-autonomous and requires its transcriptional activity.
Conclusions:
Our findings demonstrate that STAT1 suppresses mammary tumor formation and its expression is frequently lost during breast cancer progression. Spontaneous mammary tumors that develop in STAT1-/- mice closely recapitulate the progression, ovarian hormone responsiveness, and molecular characteristics of human luminal breast cancer, the most common subtype of human breast neoplasms, and thus represent a valuable platform for testing novel treatments and detection modalities.
by Sabine Kasimir-Bauer
19 Jan 2012 at 6:00pm
IntroductionThe presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502 primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and clinicopathological data of the patients.
Methods:
2 x 5 ml blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [TWIST1, Akt2, PI3Kalpha] and separately for the tumor stem cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.
Results:
97% of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts, respectively. CTCs were detected in 97/502 (19%) patients. At least one of the EMT markers was expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no correlation was found between BM status and CTC positivity (p=0.41). The presence of CTC, EMT and ALDH1 expression was not correlated to any of the prognostic clinical markers.
Conclusion:
Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in a prospective trial.
|
Yahoo! Health News
by Genevra Pittman
3 Feb 2012 at 3:00am
NEW YORK (Reuters Health) - Kids who were breastfed as babies may have better lung function, and a lower risk of asthma, than those who were formula-fed, two new reports suggest. Researchers said that past studies have found conflicting results wh...
by Tan Ee Lyn
3 Feb 2012 at 4:51am
(Reuters) - Allergan Inc, maker of wrinkle treatment Botox, eye drops and obesity treatments, said it will rely less on the United States for revenue in coming years as its products gain wider acceptance in Asia, particularly China. The company on...
by Kate Kelland, Health and Science Correspondent
3 Feb 2012 at 7:29am
LONDON (Reuters) - In June 2000, when American medical regulators posted a warning letter on the Internet about problems at a breast-implant maker in southern France, French authorities didn't pay much attention. A U.S. Food and Drug Administr...
by CLARKE CANFIELD
3 Feb 2012 at 7:52am
A 9-year-old Maine girl is home from a Boston hospital healthy, active and with high hopes — and a new stomach, liver, spleen, small intestine, pancreas, and part of an esophagus to replace the ones that were being choked by a huge tumor.
3 Feb 2012 at 8:04am
(HealthDay News) -- Preparations for successful breast-feeding begin during pregnancy.
3 Feb 2012 at 8:04am
(HealthDay News) -- Toddler tantrums can challenge even the most patient parent, but being firm and consistent can help you discipline your toddler in an effective, loving way.
by Jessica Wohl
3 Feb 2012 at 9:02am
(Reuters) - Walgreen Co is being hit by its withdrawal from the Express Scripts Inc pharmacy network and by a much-weaker-than-expected flu season, leading it to temper its expectations for the number of prescriptions it will fill this year. Walgr...
by MARIA CHENG
3 Feb 2012 at 9:16am
Malaria may be killing around twice as many people as experts previously thought, and it could also be hitting older children and adults — long considered the least susceptible — a new study suggests.
3 Feb 2012 at 10:28am
NEW YORK (Reuters) - Billionaire New York City Mayor Michael Bloomberg pledged on Thursday to give $250,000 of his own money to the Planned Parenthood Federation of America after breast cancer charity Susan G. Komen for the Cure withdrew funding f...
3 Feb 2012 at 10:28am
WASHINGTON (Reuters) - Some two dozen Democrats in the Senate on Thursday called on breast cancer charity Susan G. Komen for the Cure to reconsider its decision to cut off funding to the Planned Parenthood Federation of America. Senators Frank Lau...
by Rodrigo Campos
3 Feb 2012 at 10:43am
NEW YORK (Reuters) - U.S. stocks rose on Friday, propelling the Nasdaq index to an 11-year high, after January's U.S. employment report sailed past expectations, boosting hopes the world's largest economy has turned a corner. The broad-bas...
by HOLLY RAMER
3 Feb 2012 at 12:22pm
Researchers who spent three years dragging sheets of fabric through the woods to snag ticks have created a detailed map they claim could improve prevention, diagnosis and treatment of Lyme disease.
by Kerry Grens
3 Feb 2012 at 1:07pm
NEW YORK (Reuters Health) - Despite concerns by some that vaccines might cause a crippling nerve disorder called Guillain-Barré syndrome, a new study finds that people who receive vaccines after previously having been diagnosed with the condition ...
by Rodrigo Campos
3 Feb 2012 at 12:21pm
NEW YORK (Reuters) - A surge in hiring last month lifted U.S. stocks on Friday, with the Nasdaq index hitting an 11-year high, as the data boosted hopes the world's largest economy has turned a corner. The broad-based gains also sent the Dow J...
by Kerry Sheridan
3 Feb 2012 at 1:52pm
A major US breast cancer foundation Friday reversed its decision to stop funding Planned Parenthood after outcry over the move sparked a political and fundraising backlash by women's health advocates.
|
